Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical effectiveness of Trelegy Ellipta vs non-Ellipta multiple inhaler triple therapy in COPD usual care
2017-004369-29Phase 4Completed
- Sponsor
- GSK
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: CAT responder proportion at week 24. Started Feb 2018; status: completed.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-004369-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004369-29.